AstraZeneca shares are trading lower after the company reported topline results from the TROPION-Lung01 phase 3 trial of datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer.
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca's shares are trading lower following the announcement of topline results from the TROPION-Lung01 phase 3 trial of datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer.
July 03, 2023 | 8:50 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AstraZeneca's stock price is trading lower after the company reported topline results from a phase 3 trial of a lung cancer drug.
The drop in AstraZeneca's stock price is likely due to the announcement of the topline results from the TROPION-Lung01 phase 3 trial. This suggests that the market may have had higher expectations for the trial results.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100